High Court Snubs Teva Bid To Stay Copaxone Invalidity Ruling

By Dan Prochilo (November 14, 2013, 1:17 PM EST) -- The U.S. Supreme Court's chief justice on Wednesday denied Teva Pharmaceuticals USA Inc.'s request to stay a lower court's invalidation of patents for Teva's lucrative multiple sclerosis drug Copaxone, enabling Mylan Inc. and Sandoz Inc. to launch competing generics next spring rather than in 2015....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!